SynthesisBrain and behavior2025
Predictive Validity of the Patient Health Questionnaire-9 for Depression in Poststroke Patients: A Systematic Review and Meta-Analysis.
Synthesis in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASYM: multimodal depression recognition via mamba-enhanced attentive feature fusion.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe Patient Health Questionnaire-9 (PHQ-9), known for its brevity and ease of use, is employed by researchers and clinical practitioners for poststroke depression (PSD) screening. However, the effectiveness of the PHQ-9 in PSD screening remains to be further validated.
methodsElectronic searches were conducted in EMBASE, PubMed, Web of Science, CNKI, and Wanfang databases using keywords including stroke, depression, and PHQ-9. The assessment tool Quality Assessment of Diagnostic Accuracy Studies-2 was utilized to evaluate the risk of bias in diagnostic studies.
resultsA total of 2049 articles were retrieved, with 9 meeting the inclusion criteria. The PHQ-9 demonstrated pooled sensitivity and specificity of 0.84 and 0.90, respectively, and a summary receiver operating characteristic (sROC) curve of 0.93. At the 10-cut-off value, pooled sensitivity, specificity, and sROC were 0.77, 0.85, and 0.86, respectively. At the 9-cut-off value, the sensitivity, specificity, and sROC were 0.87, 0.85, and 0.92, respectively. At the 5-cut-off value, sensitivity, specificity, and sROC are 0.90, 0.91, and 0.96, respectively. No publication bias was identified.
conclusionThe PHQ-9 is an effective tool for screening poststroke depressive symptoms with significant clinical utility. However, further research is needed to establish optimal diagnostic thresholds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.